期刊文献+

新辅助化疗对ⅡB期骨肉瘤细胞Cyclin D1、Bcl-2、PCNA和P-gp表达的影响 被引量:3

Influence of neoadjuvant chemotherapy on expression of Cyclin D1,Bcl-2,PCNA and P-gp in Ⅱ B osteosarcoma cells
在线阅读 下载PDF
导出
摘要 目的探讨新辅助化疗对骨肉瘤组织中细胞周期素D1(CyclinD1)、Bcl-2、增殖细胞核抗原(proliferatingcellnuclearantigen,PCNA)和P-糖蛋白(P-glycoprotein,P-gp)表达的影响,及与肿瘤细胞坏死率(tumorcellnecrosisrate,TC-NR)的关系。方法应用免疫组织化学技术检测化疗前后23例骨肉瘤组织标本中CyclinD1、Bcl-2、PCNA和P-gp的表达,并计算TCNR。结果新辅助化疗前CyclinD1、Bcl-2、PCNA和P-gp的阳性表达率分别为73.9%(17/23)、69.6%(16/23)、91.3%(21/23)和21.7%(5/23),新辅助化疗后的阳性表达率分别为52.2%(12/23)、34.8%(8/23)、43.5%(10/23)和56.5%(13/23)。化疗后,骨肉瘤组织中Bcl-2、PCNA的表达低于化疗前,P值分别为0.039和0.034;P-gp高于化疗前,P=0.021;CyclinD1的表达差别无统计学意义,P=0.180。化疗前CyclinD1、Bcl-2、PCNA和P-gp的表达与TCNR无相关性,P值分别为0.155、0.371、1.000和0.640;而化疗后Bcl-2、PCNA和P-gp的表达与TCNR呈负相关,P值分别为0.009、0.012和0.015;CyclinD1的表达与TCNR无相关性,P=0.100。结论新辅助化疗可能通过抑制肿瘤细胞的增殖和促进肿瘤细胞的凋亡达到杀灭骨肉瘤细胞的目的;同时,由于MDR的过度表达,增加骨肉瘤细胞对化疗药物的耐药性。检测化疗前CyclinD1、Bcl-2、PCNA和P-gp在肿瘤细胞中的表达尚难以预测骨肉瘤的化疗疗效。 OBJECTIVE:To study the influence of neoadjuvant chemotherapy on expression of Cyclin D1, Bcl-2, PCNA and P-gp in osteosarcoma cells and the relationship between the expression and TCNR. METHODS: With immunohistochemical technology,the expression of Cyclin D1, Bcl-2, PCNA and P-gp were determined in 23 cases of osteosarcoma and TCNR was calculated. RESULTS: The positive expression rate of Cyelin D1,Bcl 2, PCNA and P-gp before neoadjavant chemotherapy was 73.9% (17/23), 69.6% (16/23), 91.3% (21/23) and 21.7%(5/23), respectively. The positive expression rate after neoadjuvant chemotherapy was 52.2 % ( 12/23), 34.8 % (8/23), 43.5%(10/23) and 56.5%(13/23), respectively. The positive expression rate of Bcl-2, PCNA after chemotherapy was much lower than that beforechemotherapy, P=0. 039,0. 034. After chemotherapy, the expression rate of P-gp was higher, P=0. 021 and there was no signficant difference in the expression of Cyclin D1, P=0. 180. No relation existed between the expression of Cyclin D1, Bcl-2 ,PCNA, P gp and TCNR before chemotherapy, P=0. 155,0. 371, 1. 000 and 0. 640. There was negative correlation between the expression of Bcl-2, PCNA, P-gp and TCNR (P=0. 009,0. 012 and 0. 015),and no relationship existed between the Cyclin D1 and the TCNR (P=0. 100) after chemotherapy. CONCLUSION: Chemotherapy could inhibit proliferation and induce apoptosis on osteosarcoma cells. At the same time, due to the overexpression of the P-gp,the drug resistance of the osteosarcoma cells was increased. The determi nation of Cyclin D1, Bcl-2,PCNA and P-gp before chemotherapy could not predict the curative effect of the chemotherapy.
作者 于秀淳 徐明
出处 《中华肿瘤防治杂志》 CAS 2006年第23期1801-1804,共4页 Chinese Journal of Cancer Prevention and Treatment
关键词 化学疗法 辅助 骨肉瘤 细胞周期蛋白D1 基因 BCL-2 增殖细胞核抗原 P-糖蛋白 chemotherapy, adjuvant osteosarcoma Cyclin DI genes, Bcl- 2 proliferating cell nuclear antigen P-glycoproteins
  • 相关文献

参考文献15

  • 1Sandberg A A,Bridge J A.Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors:osteosarcoma and related tumors[J].Cancer Genet Cytogenet,2003,145 (1):1 -30.
  • 2于秀淳,刘晓平,周银,李开华.MMIA术前化疗在骨肉瘤保肢术中的意义[J].肿瘤防治研究,2003,30(3):217-220. 被引量:18
  • 3Sakayama K,Fujibuchi T,Kidani T,et al.Proliferative activity of osteosarcoma cells:comparison of osteoblastic and nonosteoblastic regions[J].J Orthop Sci,2003,8(5):678-682.
  • 4Belchis D A,Gocke C D,Geradts J.Alterations in the RB,p16,and cyclin D1 cell cycle control pathway in osteosarcomas[J].Pediatr Pathol Mol Med,2000,19(4):377-389.
  • 5Benassi M S,Molendini L,Gamberi G,et al.Altered G1 phase regulation in osteosarcoma[J].Int J Cancer,1997,74(5):518-522.
  • 6Maitra A,Roberts H,Weinberg A G,et al.Loss of p16(INK4a)expression correlates with decreased survival in pediatric osteosarcomas[J].Int J Cancer,2001,95 (1):34-38.
  • 7Molendini L,Benassi M S,Magagnoli G,et al.Prognostic signifi cance of cyclin expression in human osteosarcoma[J].Int J Oncol,1998,12(5):1007-1011.
  • 8Ewen M E,Sluss H K,Sherr C J,et al.Functional interactions of the retinoblastoma protein with mammalian D-type cyclins[J].Cell,1993,73(3):487-497.
  • 9Yang Q,Sakurai T,Yoshimura G,et al.Expression of Bcl-2 but not Bax or p53 correlates with in vitro resistance to a series of anticancer drugs in breast carcinoma[ J ].Breast Cancer Res Treat,2000,61(3):211-216.
  • 10Posl M,Amling M,Werner M,et al.Osteosarcoma-apoptosis and proliferation.Study of Bcl-2 expression[J].Pathologe,1994 Dec,15(6):337-344.

二级参考文献6

  • 1Bramwell V. H. C. The role of chemotherapy in management of nonmetastatic operable extremity osteosarcoma[J]. Semi Oncol, 1997,24(5):561-71.
  • 2Bacci G. Picci P. Ruggieri P, et al. Primary chemotherapy and delayed surgery (neoadjuvant chemotherapy) for osteosarcoma of the extremities. The Istituto Rizzoli Experience in 127 patients treated preoperatively with intravenous methotrexate (high versus moderate doses) and intraarterial cisplatin[J]. Cancer, 1990, 65:2539-2553.
  • 3Goorin A, Baker A, Gieser P, et al. No evidence for improved event free survival (EFS) with presurgical chemotherapy (PRE) for nonmetastaic extremity osteogenic sarcoma (OGS) : Preliminary results of randomized pediatric oncology group (POG) trial 8651[J].Pro Am Soc Clin Oncol, 1995(abstr),14:444-456.
  • 4马忠泰.创造条件,推进骨肉瘤大剂量综合化疗的规范化[J].中华骨科杂志,1999,19(1):5-6. 被引量:31
  • 5胡永成,胡永成.全国骨肉瘤化疗座谈会纪要[J].中华骨科杂志,1999,19(1):7-9. 被引量:56
  • 6徐瑾.化疗所致恶性骨肿瘤坏死的组织学评估及其意义[J].中华骨科杂志,1999,19(1):23-23. 被引量:7

共引文献17

同被引文献23

  • 1黄云鹏,林建华,林志雄,庄建良,陈一峰,曾志远,汤海峰,吴少明.化疗对骨肉瘤α_V和β_3整合素表达影响的研究[J].中华肿瘤防治杂志,2008,15(13):1018-1021. 被引量:3
  • 2樊祥山,孟凡青,章宜芬,吴鸿雁,王景美.骨肉瘤组织芯片的制作及其免疫组织化学应用[J].东南大学学报(医学版),2006,25(2):104-107. 被引量:8
  • 3Guo W,Yang R,Tang X,et al.Neoadjuvant chemotherapy for ostrosarcoma[J].Natl Med J China,2004,84(14):1186-1190.
  • 4Mika MS,Maija T,Aarne HK,et al.Osteosarcoma in Finland from 1971 through 1990 A nationwide study of epidemiology and outcome[J].Acta Orthopaedica,2008,79 (6):861-866.
  • 5Ahmed A,Gilbert-Barness E,Lacson A.Expression of c-kit in Ewing family of tumors:a comparison of different immunohistochemical protocols[J].Pediatr Dev Pathol,2004,7(4):342-347.
  • 6de Alava E,Antonescu CR,Panizo A,et al.Prognostic impact of P53 status in Ewing sarcoma[J].Cancer,2000,89(4):783-792.
  • 7Stiller CA,Passmore SJ,Kroll ME,et al.Patterns of care and survival for patients aged under 40 years with bone sarcoma in Britain,1980-1994[J].Br J Cancer,2006,94(1):22-29.
  • 8Zuffa E,Mancini M,Brusa G,et al.P53 oncosuppressor influences selection of genomic imbalances in response to ionizing radiations in human osteosarcoma cell line SAOS-2[J].Int J Radiat Biol,2008,84(7):591-601.
  • 9Lengner CJ,Steinman HA,Gagnon J,et al.Osteoblast differentiation and skeletal development are regulated by Mdm2-p53 signaling[J].J Cell Biol,2006,172(6):909-921.
  • 10Lonardo F,Ueda T,Huvos AG,et al.p53 and MDM2 alterations in osteosarcomas:correlation with clinicopathologic features and proliferative rate[J].Cancer,1997,79(8):1541-1547.

引证文献3

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部